ClinicalTrials.gg
CompletedNCT04173403Updated Mar 2, 2023

A Long-term Study of AK102 in Patients With Hypercholesterolemia

A Phase 2 interventional study of 450mg AK102 and 300mg AK102 in Hypercholesterolemia, sponsored by Akeso. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
796
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Enrollment
12th of 53
796 · median 207
Started
2019
with 5 others
Phase 2
6 of 59
none open now
Registered
22nd of 59
by date
Lead sponsor
3 of 59
Akeso

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 12th largest by enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2019, is one of 6 in phase 2, and was the 22nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

This is a phase II, open-label, non-controlled, extended study. The main objective of this study is to evaluate the long-term efficacy and safety of AK102 in combination with basic lipid-lowering therapy in patients with hypercholesterolemia. Subjects who have participated in the AK102 studies and have completed the last visit,and who, in the opinion of the investigator, are likely to benefit from continued treatment will be enrolled in this study.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Body weight ≥ 40 kg for both men and women.
  3. Participated in the AK102-202 study, and completed the AK102-202 study last visit.

Exclusion criteria

Exclusion Criteria:

  1. Poor compliance in AK102-202 study per investigator's judgement.
  2. AE that led to permanent discontinuation of AK102 occurred during the AK102-202 study period.
  3. Prior use of PCSK9 inhibitors other than AK102.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
796 participants (actual)

Study arms

  • Experimental
    AK102

    450mg AK102, Q4W, subcutaneous injection; OR 300mg AK102, Q4W, subcutaneous injection;OR 150mg AK102, Q4W, subcutaneous injection;

    Drug: 450mg AK102 · Drug: 300mg AK102 · Drug: 150mg AK102 · Drug: Statins and/or Ezetimibe

Interventions

  • Drug450mg AK102

    AK102 Q4W

  • Drug300mg AK102

    AK102 Q4W

  • Drug150mg AK102

    AK102 Q2W

  • DrugStatins and/or Ezetimibe

    Drug pages: Statins · Ezetimibe

    Lipid-lowering therapies

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 52

    Time frame: Week 52

Secondary outcomes

  1. Incidence of treatment-emergent adverse events as assessed by CTCAE V5.0

    Time frame: From baseline through 52 weeks

  2. Percent Change From Baseline in High-density lipoprotein (HDL) cholesterol

    Time frame: From baseline through 52 weeks

  3. Percent Change From Baseline in non High-density lipoprotein (non-HDL) cholesterol

    Time frame: From baseline through 52 weeks

  4. Percent Change From Baseline in Serum Triglyceride (TG) cholesterol

    Time frame: From baseline through 52 weeks

  5. Percent Change From Baseline in Apolipoprotein B (Apo B)

    Time frame: From baseline through 52 weeks

  6. Percent Change From Baseline in Apolipoprotein A-I (Apo A-I)

    Time frame: From baseline through 52 weeks

  7. Percent Change From BaPercent Change From Baseline in Total Cholesterol(TC)

    Time frame: From baseline through 52 weeks

  8. Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

    Time frame: From baseline through 52 weeks

  9. Concentrations of AK102 in Serum

    Time frame: From baseline through 52 weeks

  10. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    The immunogenicity of AK102 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies.

    Time frame: From baseline through 52 weeks

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing 100000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Feb 2023, 39 months.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 39 months is above that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2019
First posted
Nov 22, 2019
StartActual
Nov 4, 2019
Primary completionActual
Feb 17, 2023
CompletionActual
Feb 17, 2023
Last update
Mar 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04173403
Lead sponsor
Akeso
Collaborators
AD Pharma (Guangdong)
Responsible party
Sponsor
First posted
Nov 22, 2019
Start date
Nov 4, 2019
Primary completion
Feb 17, 2023
Completion
Feb 17, 2023
Last update
Mar 2, 2023

Study contacts

Shuyang Zhang
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion